Tag Archives: technology

Navigating JPM Week: A Guide to RESI’s 2026 Event Lineup 

18 Nov

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

As the life science world converges on San Francisco for J.P. Morgan Healthcare Week in January 2026, the RESI Conference plays a central role, and its website’s dedicated “JPM Week Events” page is an essential resource for attendees and stakeholders alike. Here’s a breakdown of what the site offers and why it’s such a valuable hub.

What Is the JPM Week Events Page?

The RESI “JPM Week Events” page is essentially a curated calendar and guide, maintained by Life Science Nation. It compiles an exhaustive list of life science–oriented events happening in parallel with JPM Healthcare Week, from early morning breakfasts to high-level receptions and symposiums.

It’s not just a list; it’s a strategic tool for entrepreneurs, investors, and corporates to plan how to maximize their time during one of the most frenetic weeks in biotech and healthcare investments.

What’s on the Agenda: Highlights from the 2026 Schedule

Here is some standout events listed for January 2026 on RESI’s page:

January 10–11:

  • San Francisco CEO | Longwood Healthcare Leaders Forum — A full-day leadership forum at the Four Seasons.
  • 9th Annual Neuroscience Innovation Forum — Focused on business development, licensing, and investment, held at the Marines’ Memorial Club.
  • PwC Executive Women’s Event — A networking event aimed at women leaders in healthcare.
  • Yafo Capital ACCESS ASIA BD Forum — A cross-border business development forum in San Francisco.

January 12:

  • RESI JPM 2026 Conference at the San Francisco Marriott Marquis.
  • AcuityMD Sunrise Partnering Breakfast — An early morning session for high-value partnering.
  • AdvaMed Member Meeting Space & Receptions — Dedicated space for AdvaMed members.
  • Incubate & DLA Piper: Innovation at a Crossroads — A policy-focused discussion on biopharma strategy in a changing global landscape.
  • Lifeblood & Goodwin MedTech CEO-only Forum — A specialized gathering for medtech CEOs.
  • MassBio Meeting Space & Receptions — Hosted by MassBio at the Parc 55 Hotel.
  • QNova LifeSciences 12th Annual Partnering Forum — A major partnering event in the Hilton Union Square.
  • PMI Biotech Reception — A dinner reception at InterContinental Mark Hopkins.
  • Aquillius Pitch Showcase — A pitching event for life sciences companies.
  • Biovia Event: Clusters of Excellence — A forum on European life science clusters and global success.
  • T2Bmeet @ JPM — A streamlined meeting event to facilitate business development and partnering.
  • Scale Biosciences JPM Happy Hour — Evening social for dealmakers.
  • STAT @ JPM26 Live — A live event by STAT News.
  • Reed Smith Reception — At the Museum of the African Diaspora.
  • Deloitte Reception — A networking evening hosted by Deloitte.

January 13:

  • Continuation of RESI JPM 2026.
  • Fierce JPM Week — A track that runs throughout JPM Week, focused on dealmaking and thought leadership.
  • Biocom California Events — Receptions, meeting space, and more at Omni San Francisco.
  • KoreaBIO / BioCentury / Sidley Austin IR Forum — Global investor relations forum.
  • LaunchBio & Inspira Innovators Social Hour — A more informal social event for early-stage founders.
  • Katten’s Diptyque Client Reception — A luxury experience for select invitees.
  • Dartmouth Offsite — Hosted at the Beacon Grand Hotel.
  • Bits in Bio Reception — For emerging biotech companies and leaders.

January 14–15:

  • Multiple networking breakfasts, partnering forums, and receptions.
  • HCPEA Women’s Mentor/Mentee Networking Breakfast on January 14.
  • 2026 Stanford Alumni in Healthcare Networking Mixer — A Stanford alumni focused event.
  • CTIP Innovator Showcase (Jan 15) — For pediatric technology innovators.
  • MBC BioLabs: Meet the Founders — Founders’ networking at a biotech incubator.
  • Toplink Conference @ JPM — A full-day conference on tech + life science.
  • And more receptions, including PCI Pharma Services, California Israel Chamber of Commerce Israel Lounge, and Destination Medical Center Discovery Exchange.

Why This Page Matters

  1. Comprehensive Planning Tool: For anyone attending JPM Week — whether founders, investors, BD execs, or scientists — having a central, curated list of relevant life science events is invaluable. Rather than navigating a sea of scattered invitations, the RESI page brings together a clean, structured schedule.
  1. Partnership Optimization: Many of the events listed are tailored for dealmaking — breakfasts, partnering forums, and pitch showcases. This makes it easier for startups to schedule and maximize high-impact interactions.
  1. Community Spotlight: The page isn’t only about formal conferences; it also highlights social events, networking mixers, and sector-specific receptions (e.g., women in healthcare, neuroscience, medtech). This helps attendees connect on both professional and personal levels.

The RESI “JPM Week Events” page is more than just a listing: it’s a strategic roadmap for navigating one of the busiest and most important weeks in healthcare investing. By consolidating diverse events, boardroom policy talks to rooftop cocktail receptions; it empowers life science professionals to plan smarter, connect deeper, and maximize their time.

For anyone participating in RESI JPM 2026, bookmarking this page is one of the first steps to making the most of the week.

Register for RESI JPM >>

Early-Stage Partnerships with Mosaic Biosciences at RESI London 

18 Nov

By Matt Stanton, VP Sales US West, Central and South America, LSN

Mara Sprouce, Director of Commercial Operations at Mosaic Biosciences, shares how their team of drug hunters and problem solvers support early-stage biotech partners from concept to candidate. In this interview, Mara discusses Mosaic’s collaborative approach to innovation, how their platform adapts to diverse modalities and target classes, and what sets them apart from a traditional CRO. She also highlights the types of partners they’re eager to meet at RESI London and what attendees can look forward to when connecting with the Mosaic team on-site.

Register for RESI London

Hot Investor Mandate: Family Office Backed Venture Fund Invests in Pre-Clinical Therapeutic Platforms Across the Globe

18 Nov

This early-stage venture fund, with offices in Western Europe, is led by a team with deep expertise across venture funding, company building, and therapeutic development. The firm is currently focused on cell and gene therapy, with particular interest in the manufacturing technologies that support these modalities. 

The firm is especially interested in therapeutic platforms at the pre-clinical stage, including cutting-edge cell therapies for regenerative medicine and autoimmune conditions that require localized manufacturing capabilities. It seeks to support breakthrough technologies at the seed stage. 

The firm typically takes an active role in its portfolio companies, frequently leading rounds, providing strategic guidance, and ensuring board-level engagement, either by taking a board seat directly or placing a qualified expert. In addition to company creation, the firm also invests in existing ventures, often syndicating with other institutional investors to support early-stage growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: VC Firm Invests in Drug Discovery Enabling Tools, Techbio, AI-Driven Applications Globally With a Focus on USA-Based Companies  

18 Nov

A pharma-tech focused venture capital firm, founded in 2022 and headquartered in the US, invests in early-stage companies and also has the capability to incubate new ventures. The firm is driven by the belief that the pharmaceutical industry represents a strong and scalable customer base, and seeks technologies that align with or enhance the pharma value chain. While open to global opportunities, the firm shows a preference for companies based in the United States. Typical investment sizes range from $2 million to $5 million, and the firm is flexible in its role, able to lead or follow in financing rounds. 

The firm invests across a broad spectrum of pharma-tech, including technologies targeting patients or providers, tech-bio platforms, drug discovery tools, AI-driven applications, supply chain innovations, and data-centric platforms. In essence, it is interested in any innovation that contributes to the pharmaceutical and life sciences value chain. The firm is disease-agnostic in its approach. 

An active investor, the firm typically takes a board seat or observer role and prefers companies that have pharmaceutical companies as at least one major customer or are built with pharma as the primary target market. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: USA-Based VC Firm Seeks Longevity-Focused Investments, Engaging in Seed to Series A Rounds

18 Nov

A venture capital firm based in the US is focused on incubating and investing in longevity-focused companies that aim to improve quality of life for older adults. The firm primarily invests at the Seed and Series A stages, with typical initial check sizes ranging from $100,000 to $500,000. The investment focus is on opportunities based in the United States. 

The firm invests broadly across the life sciences and healthcare sectors, provided there is a clear connection to aging and longevity. Areas of interest include healthcare quality and cost, care capacity, healthcare benefits activation, aging in place, and financial longevity. The firm has made investments in medical devices, diagnostics, and digital health companies, and currently maintains an active portfolio of more than 15 companies. It generally does not invest in biotech. The firm is open to backing companies at the earliest stages of development. 

There are no specific requirements regarding company structure or founding team experience. The firm is flexible in its role and may choose to lead or co-invest depending on the opportunity. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Late-Stage Venture & Growth Equity Investor Backing De-Risked Therapeutics and Medical Device Opportunities

18 Nov

A venture capital and private equity firm focuses on investments in the life sciences sector, with a primary emphasis on pharmaceuticals and therapeutics, and a secondary interest in medical devices. The firm invests from Series A through growth-stage transactions and is currently deploying capital from its third fund. Typical investment sizes range from $10 million to $40 million. 

The firm prioritizes opportunities with a de-risked clinical development pathway, such as those involving repurposed or reformulated drugs, established mechanisms of action, 505(b)(2) regulatory strategies, or programs with proof-of-concept clinical data. For therapeutic assets, the firm primarily targets clinical-stage companies, ideally with completed Phase I trials. For medical devices, the firm considers clinical-stage opportunities with a clear regulatory and commercialization path. The firm is indication-agnostic but maintains a strong interest in 505(b)(2) products.  
 
The firm seeks companies with a clearly defined path to regulatory approval, supported by robust intellectual property and market exclusivity. It plays an active role in its portfolio companies and takes a board seat in every investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

From Lab to Market: Why Life Science Companies Are Drawn to Singapore 

12 Nov

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

LSN is proud to announce our partnership with Enterprise SG for RESI JPM 2026, to foster meaningful conversations on global life science innovation, investment and cross-border collaboration. Learn how Singapore is a dynamic launchpad for innovation and home to cutting-edge startups ready to collaborate on your next breakthrough. Join us at our upcoming panel on January 12 to find out more! 

As global healthcare challenges intensify, innovative biomedical technologies from Asia are stepping up to drive change, translating life science research into real-world solutions. Increasingly, investors, corporates, startups, and healthcare systems around the world are seeing the urgency in bridging the East and West to improve healthcare outcomes and deliver value-based care.

Singapore, located at the heart of Asia, is a dynamic hub for biomedical innovation, driven by a strong network of global investors, researchers, mentors, and innovators. With decades of sustained government investments and a robust talent pipeline from world-class universities and research institutes, it is home to over 500 biomedical and medtech companies. The ecosystem has attracted venture capitalists and venture builders like MPM BioImpact, Polaris Partners, and Flagship Pioneering, as well as global pharma leaders such as Pfizer, Roche, and Johnson & Johnson. These players work closely with government agencies, like Enterprise Singapore, that drive startup development, provide patient funding, expertise, infrastructure, and networks crucial for producing globally competitive solutions.

Singapore’s strategic position as a bridge between Asian and global markets enables it to play an outsized role in driving biomedical advancements. This works both ways, as a gateway for global companies to access the growing opportunities in Asia, and as a springboard for regional companies to expand worldwide. For example, through partnerships with healthcare organisations like Cedars-Sinai and Mayo Clinic in the US, Enterprise Singapore supports Singapore startups to test and scale their solutions in overseas markets, facilitating a bi-directional flow of innovation to improve healthcare for communities.

Join Enterprise Singapore at the ‘Asia Cross Border Investments Panel’ to explore how cross-border capital, talent, and technologies are converging to drive breakthroughs in precision medicine, innovative therapies, and next-generation diagnostics. The panel will take place on January 12, 2026, from 11:00 am to 12:00 pm at RESI JPM by LSN, held at the Marriott Marquis, San Francisco. Learn from prominent industry leaders how transcontinental partnerships, including those with Singapore, are shaping the future of healthcare innovation – from discovery to global commercialisation.

To join the conversation, please contact Claire Jeong, VP of Investor Research, Asia BD, at c.jeong@lifesciencenation.com.